DreamIt Ventures, a pre-seed stage venture firm, has announced that Kaiser Permanente will be joining its Baltimore accelerator, joining Northrop Grumman Corporation, BioHealth Innovation, and Johns Hopkins University.
The nine start-ups will undergo a four month long program including guidance on resource access, seed capital, and the healthcare, technology, and business marketplaces. The organizations will also be mentored the high-profile partners.
DreamIt Ventures‘ Baltimore accelerator is adding another prestigious partner to its ranks: Kaiser Permanente will join the organization’s leadership team, alongside Johns Hopkins University, Northrop Grumman Corporation and BioHealth Innovation.
“We look forward to working with these very promising new healthcare technology companies where we can provide access to industry leading health professionals and a real world laboratory to test the usability and effectiveness of next generation technology solutions” Kim Horn, president of the Kaiser Foundation Health Plan of the Mid-Atlantic States, Inc., said in a statement.
Five Baltimore companies are among the startups that will be the first through a new health IT accelerator in the city.
A total of nine companies from around the world were selected for DreamIt Health Baltimore’s inaugural program, which officially begins Jan. 20. The accelerator program lasts four months and includes seed funding, mentorship from veteran entrepreneurs, workspace and other resources to help participants’ businesses take off. It is designed help startup companies power through early problems and prepare for the market.
Johns Hopkins was a city within a city.
A gleaming, state-of-the-art, wonder-what’s-going-on-in-there mansion smack in the middle of a rundown Baltimore neighborhood.
Hopkins has always been involved in Baltimore to some extent. The university and the health system employ roughly 50,000 people in the Baltimore area, making them the two largest employers here. Their construction projects inject millions into the local economy. But Hopkins’ reputation is as a world-renowned medical research giant
Johns Hopkins’ quest to build bridges in Baltimore
Q&A with Johns Hopkins University President Ronald Daniels
Q&A with Johns Hopkins Hospital President Ronald Peterson
Q&A with Johns Hopkins’ new tech transfer chief
Here’s a look at some Johns Hopkins spinoffs
Johns Hopkins is making primary care a priority
Johns Hopkins’ storied history in medical discoveries
Johns Hopkins’ reach goes well beyond Baltimore’s borders
Johns Hopkins’ top priorities include EBDI, Homewood
Abstracts are solicited for oral or poster presentation. Submissions will be reviewed and selected by the conference technical program committee. Abstract preparation guidelines.
Please visit the symposia pages for information about the scope and aims of each symposium and to learn about our prestigious invited/keynote speakers
Important Dates
Authors of research submissions, upon acceptance, must register for the conference.
Johns Hopkins University’s board of trustees has voted to renew the contract of President Ronald J. Daniels, keeping him at the helm of the nation’s first research university for another five years. The unanimous board action today signaled a strong and clear endorsement for Daniels, who has been instrumental in leading and advancing the mission of the university.
The reappointment, announced by board chairman Jeffrey H. Aronson, extends Daniels’ contract to 2019.
Venture capitalists more than doubled their investment in companies based Baltimore- and Washington, D.C.-area companies in 2013.
Venture firms invested more than $1.5 billion in the region in 2013, making that the biggest year for investment since 2001, according to the latest MoneyTree Report from PricewaterhouseCoopers and the National Venture Capital Association. Maryland companies took in 43 percent of that investment money.
Funding and Research Opportunities
The following funding opportunity announcements from the NHLBI or other components of the National Institutes of Health, might be of interest:
NIH Guide Notices:
Please note that most links to RFAs, PAs, and Guide Notices will take you to the NIH Web site. RFPs will take you to FedBizOpps. Links to RFPs will not work past their proposal receipt date. Archived versions of RFPs posted on FedBizOpps can be found on the FedBizOpps site using the FedBizOpps search function. Under “Document to Search,” select Archived Documents.
Underwriters have snapped up another 1 million shares of GlycoMimetics Inc. stock, the Gaithersburg biotech announced this week, marking the close of its $64.4 million initial public offering.
GLYC debuted on the Nasdaq last week in the Washington region’s first IPO of 2014, selling a total 8 million shares at $8 apiece. Net proceeds to the company will be around $57.4 million, much of which will pay expenses to advance one of its oncology drug candidates through the clinic.
Thursday, January 30 | 1:30 – 6:30 pm
Shark Tank is a one-of-a-kind event where industry experts pose stimulating questions to CBID MSE student teams about their medtech projects. A mid-year design project showcase and reception will follow the challenging throw down.
